Objective: To study the clinical efficacy and safety on the treatment of female climacteric syndrome (CS) by Femoston. Methods: A total of 108 cases of CS patients were selected and randomly divided into two groups, the control group and treatment group, each group had 54 cases. The control group was treated with estradiol vale rate, and the treatment group was treated with Femoston, continue taking for 16 weeks, and then compared the clinical effect, Kupperman score, the change of main symptom integral and detected the change of serum indicators. Results: After the end of the follow-up, the total clinical effective rate of the control group and treatment group were 77.8% and 88.9% respectively, the differences between two groups were significantly (P<0.05). Before and after treatment, the Kupperman score was significantly reduced (P<0.05), menopausal symptoms of the both group were effectively improved (P<0.05), and statistically difference also between the two groups (P<0.05). After one year, the serum estradiol (E2) levels of both group increased significantly, the luteinizing hormone (LH) levels of both group reduced significantly, but no statistical difference between two groups (P>0.05). The follicle stimulating hormone (FSH) level declined obviously, and the treatment group was significantly lower than the control group (P<0.05). After the end of the follow-up, the treatment group total serum cholesterol (TG), triglycerides (TC), low density fatty acids (LDL-C) were markedly reduced, and lower than the control group (P<0.05 or P<0.01), high density fatty acid increased (HDL-C) was markedly increased, and higher than the control group (P<0.05). There was no significant difference in the adverse reaction rate between the two groups (P>0.05). Conclusion: Femoston can effectively improve the endocrine level and clinical symptoms for the menopausal women.